

ADJUSTED COMPARISON BETWEEN ELOTUZUMAB AND CARFILZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE AS SALVAGE THERAPY FOR MULTIPLE MYELOMA PATIENTS.

Fortunato Morabito^{1,2}, Elena Zamagni^{3,4}, Concetta Conticello⁵, Vincenzo Pavone⁶, Salvatore Palmieri⁷, Sara Bringhen⁸, Monica Galli⁹, Silvia Mangiacavalli¹⁰, Daniele Derudas¹¹, Elena Rossi¹², Roberto Ria¹³, Lucio Catalano¹⁴, Paola Tacchetti³, Giuseppe Mele¹⁵, Iolanda Donatella Vincelli¹⁶, Enrica Antonia Martino¹⁷, Ernesto Vigna¹⁷, Cirino Botta¹⁷, Antonella Bruzzese¹⁷, Anna Mele⁶, Lucia Pantani³, Serena Rocchi^{3,4}, Bruno Garibaldi⁵, Nicola Cascavilla¹⁸, Stelvio Ballanti¹⁹, Giovanni Tripepi²⁰, Ferdinando Frigeri²¹, Antonetta Pia Falcone¹⁸, Clotilde Cangialosi²², Giovanni Reddiconto²³, Giuliana Farina²¹, Marialucia Barone²⁴, Ilaria Rizzello^{3,4}, Pellegrino Musto²⁵, Valerio De Stefano¹², Maurizio Musso²⁶, Maria Teresa Petrucci²⁷, Massimo Offidani²⁸, Antonino Neri²⁹, Nicola Di Renzo²³, Francesco Di Raimondo⁵, Mario Boccadoro⁸, Michele Cavo^{3,4} and Massimo Gentile¹⁷.

¹Biothecnology Research Unit, AO of Cosenza, Cosenza, Italy; ²Hematology and Bone Marrow Transplant Unit, Hemato-Oncology Department, Augusta Victoria Hospital, East Jerusalem, Israel;

³IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy; ⁴Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy; ⁵Division of Hematology, Azienda Policlinico-OVE, University of Catania, Catania, Italy; ⁶Department of Hematology and Bone Marrow Transplant, Hospital Card. G. Panico, Tricase (LE), Italy; ⁷Hematology Unit, Ospedale Cardarelli, Napoli, Italy; ⁸Division of Hematology, University of Torino, AOU Città della Salute e della Scienza di Torino, Italy; ⁹Hematology and Bone Marrow Transplant Unit, Azienda Socio-Sanitaria Territoriale-Papa Giovanni XXIII, Bergamo, Italy; ¹⁰Hematology Division, Department of Hematology-Oncology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy; ¹¹Department of Hematology, Businco Hospital, Cagliari, Italy; ¹²Istituto di Ematologia, Università Cattolica, Fondazione Policlinico Gemelli IRCCS, Roma, Italy; ¹³Department of Biomedical Science, University of Bari "Aldo Moro" Medical School, Internal Medicine "G. Baccelli", Policlinico, Bari, Italy; ¹⁴Hematology, AUOP "Federico II", Naples, Italy; ¹⁵Department of Hematology, Hospital Perrino, Brindisi, Italy; ¹⁶Hematology Unit, Department of Hemato-Oncology and Radiotherapy, Great Metropolitan

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/EJH.13723](#)

This article is protected by copyright. All rights reserved

Hospital "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy; ¹⁷Hematology Unit AO of Cosenza, Cosenza, Italy; ¹⁸Department of Hematology and Bone Marrow Transplant, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy; ¹⁹Institute of Haematology and Stem Cell transplantation, Ospedale Santa Maria della Misericordia, University of Perugia, Perugia, Italy; ²⁰Nephrology Center of National Research Institute of Biomedicine and Molecular Immunology, Reggio Calabria, Italy; ²¹UOC Ematologia a Indirizzo Oncologico, AORN "Sant'Anna e San Sebastiano", Caserta, Italy; ²²U.O.C. Ematologia A. O. Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy; ²³Department of Hematology, Hospital Vito Fazzi, Lecce, Italy; ²⁴Onco-Hematology, "Tortora" Hospital, Pagani, SA, Italy; ²⁵Hematology Section, University of Bari, Italy; ²⁶U.O.C. OncoEmatologia e TMO, Dipartimento Oncologico, La Maddalena, Palermo, Italy; ²⁷Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Italy; ²⁸Hematology Unit, AOU Ospedali Riuniti di Ancona, Italy; ²⁹Hematology Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.

Correspondence: Fortunato Morabito, MD, Biotechnology Research Unit, AO of Cosenza, Contrada San Nicola, Cosenza, Italy; 87100 Cosenza, Italy; e-mail: f.morabito53@gmail.com; ph: +39-0984-015863; fax: +39-0984-681329.

Massimo Gentile, MD, Hematology Unit, AO of Cosenza, Italy; 87100 Cosenza, Italy; viale della Repubblica snc, e-mail:massim.gentile@tiscali.it; ph: +39-0984-681329; fax: +39-0984-681329.

Text word count: 3790; Table: 3; Figure: 5; Supplementary Figures 2.

Abstract word count: 249.

References: 33.

Article Type: Original article

Running title: Adjusted comparison between KRd *versus* EloRd: a clinical practice study.

Keywords: Elotuzumab, carfilzomib, lenalidomide, dexamethasone, multiple myeloma, salvage therapy.

Significance statement

- In this current study we weighed the relative usefulness of EloRd over KRd, comparing a multicenter retrospective EloRd cohort with four multicenter retrospective KRd cohorts, all including RRMM cases treated outside of clinical trials.

- This current clinical practice study's overall results demonstrate that KRd therapy offers a superior outcome than EloRd.

Abstract

The lack of a randomized trial comparing carfilzomib (K) *versus* elotuzumab (Elo) associated with lenalidomide and dexamethasone (Rd) prompted us to assess the relative usefulness of one triplet over the other.

This article is protected by copyright. All rights reserved

Five independent retrospective cohorts of 883 relapsed/refractory multiple myeloma (RRMM) patients, including 300 EloRd and 583 KRd cases, outside clinical trials, entered this non-randomized comparison. KRd cohort accounted for a higher incidence of younger patients, cases with >3 lines of therapy, already exposed to lenalidomide, International Staging System (ISS) stage III, and abnormal lactic dehydrogenase (LDH) level compared to EloRd cohort. Moreover, cytogenetic risk categories, detected in roughly one-third of cases, were equally distributed between the two therapy arms.

The probability of CR+VGPR response was significantly higher in KRd (n=314, 53.9%) than in EloRd patients (n=111, 37.0%). Likewise, the cumulative incidence function of CR+VGPR, taking into account the competitive risk of death, was significantly higher in KRd arm patients than those in the EloRd arm (P=0.003). Moreover, KRd treatment significantly reduced the progression or death risk by 46% in an adjusted multivariate analysis (HR: 0.54, 95% CI 0.42-0.69, P<0.0001).

Finally, in an adjusted illness progression/death model, the effect of KRd *versus* EloRd was of higher magnitude among those who achieved CR+VGPR (-39% hazard ratio reduction, P=0.02) than among those who achieved <VGPR (-29% hazard ratio reduction, P=0.007).

With limitations characteristic to any retrospective analysis, this current clinical practice study's overall results demonstrated potential benefits of KRd therapy compared to EloRd. This observation may help the daily clinical practice.